Using Bcr-Abl to examine mechanisms by which Abl kinase regulates morphogenesis in Drosophila

被引:23
|
作者
Stevens, Traci L. [1 ,3 ]
Rogers, Edward M. [1 ]
Koontz, Laura M. [1 ]
Fox, Donald T. [1 ]
Homem, Catarina C. F. [1 ]
Nowotarski, Stephanie H. [1 ]
Artabazon, Nicholas B. [3 ]
Peifer, Mark [1 ,2 ]
机构
[1] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Randolph Macon Coll, Dept Biol, Ashland, VA 23005 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1091/mbc.E07-01-0008
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Signaling by the nonreceptor tyrosine kinase Abelson (Abl) plays key roles in normal development, whereas its inappropriate activation helps trigger the development of several forms of leukemia. Abl is best known for its roles in axon guidance, but Abl and its relatives also help regulate embryonic morphogenesis in epithelial tissues. Here, we explore the role of regulation of Abl kinase activity during development. We first compare the subcellular localization of Abl protein and of active Abl, by using a phosphospecific antibody, providing a catalog of places where Abl is activated. Next, we explore the consequences for morphogenesis of overexpressing wild-type Abl or expressing the activated form found in leukemia, Bcr-Abl. We find dose-dependent effects of elevating Abl activity on morphogenetic movements such as head involution and dorsal closure, on cell shape changes, on cell protrusive behavior, and on the organization of the actin cytoskeleton. Most of the effects of Abl activation parallel those caused by reduction in function of its target Enabled. Abl activation leads to changes in Enabled phosphorylation and localization, suggesting a mechanism of action. These data provide new insight into how regulated Abl activity helps direct normal development and into possible biological functions of Bcr-Abl.
引用
收藏
页码:378 / 393
页数:16
相关论文
共 50 条
  • [31] Selective killing of BCR-ABL positive cells with a specific inhibitor of the ABL tyrosine kinase
    Druker, BJ
    Ohno, S
    Buchdunger, E
    Tamura, S
    Zimmermann, J
    Lydon, NB
    CANCER GENES: FUNCTIONAL ASPECTS, 1996, 7 : 255 - 267
  • [32] Response: Too much BCR-ABL to live on, but too little BCR-ABL to die on?
    Burchert, Andreas
    Neubauer, Andreas
    Hochhaus, Andreas
    BLOOD, 2012, 119 (12) : 2965 - 2966
  • [33] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    Druker, BJ
    Tamura, S
    Buchdunger, E
    Ohno, S
    Segal, GM
    Fanning, S
    Zimmermann, J
    Lydon, NB
    NATURE MEDICINE, 1996, 2 (05) : 561 - 566
  • [34] Comparison of the intrinsic kinase activity and substrate specificity of c-Abl and Bcr-Abl
    Wu, JZJ
    Phan, W
    Lam, KS
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (17) : 2279 - 2284
  • [35] Induction of Autophagy by Imatinib Sequesters BCR-ABL in Autophagosomes and Reduces BCR-ABL Expression
    Nyhan, M.
    Elzinga, B.
    Crowley, L.
    O'Donovan, T.
    Orfali, N.
    O'Sullivan, G. C.
    Cahill, M.
    McKenna, S. L.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 30 - 30
  • [36] Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects
    B Perazzona
    H Lin
    T Sun
    Y Wang
    R Arlinghaus
    Oncogene, 2008, 27 : 2208 - 2214
  • [37] Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
    Ren, R
    NATURE REVIEWS CANCER, 2005, 5 (03) : 172 - 183
  • [38] Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects
    Perazzona, B.
    Lin, H.
    Sun, T.
    Wang, Y.
    Arlinghaus, R.
    ONCOGENE, 2008, 27 (15) : 2208 - 2214
  • [39] Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
    Afsar Ali Mian
    Anna Metodieva
    Susanne Badura
    Mamduh Khateb
    Nili Ruimi
    Yousef Najajreh
    Oliver Gerhard Ottmann
    Jamal Mahajna
    Martin Ruthardt
    BMC Cancer, 12
  • [40] Inhibition of Bcr-Abl kinase activity with imatinib induces poly (ADP) ribosylation in Bcr-Abl positive hematopoietic cells.
    Moehring, A
    van der Kuip, H
    Wohlbold, L
    Duyster, J
    Aulitzky, WE
    BLOOD, 2003, 102 (11) : 202B - 202B